Saturday - November 23, 2024
AstraZeneca: Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients With Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
November 13, 2024
WILMINGTON, Delaware, Nov. 13 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

AstraZeneca and Daiichi Sankyo's new application is based on the TROPION-Lung05 Phase II trial and supported by data from additional trials including TROPION-Lung01

Previously submitted BLA based on TROPION-Lung01 Phase III trial for

patients with nonsquamous NSCLC has been voluntarily withdrawn

* * *
< . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products